NEOADJUVANT PUBLICATIONS & ABSTRACTS

Neoadjuvant data


Neoadjuvant publications

Evidence / Neoadjuvant

Impact of Neoadjuvant Endocrine Therapy on Tumor Transcriptome in Patients With Early-Stage Breast Cancer From the FLEX Trial

PUBLICATION: San Antonio Breast Cancer Symposium 2022 TITLE: Impact of neoadjuvant endocrine therapy on tumor transcriptome in patients with early-stage breast cancer from the FLEX trial AUTHORS: Mehran Habibi1, Danijela Jelovac1, Rima Couzi1, Cesar Agusto Santa-Maria1, Catherine Klein1, Marissa White1, Nivali Naik1, Jennifer Wei2, Yen Huynh2, Architha Ellappalayam3, Lisa Read More

Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint

PUBLICATION: ASCO 2021 ย  Authors Joyce Oโ€™Shaughnessy1, Virginia G. Kaklamani2, Yuan Yuan3, Julie Barone4, Sami Diab5, Jennifer A. Crozier6, Pat W. Whitworth7, Karen L. Tedesco8, Robert Maganini9, Rakhshanda Layeequr Rahman10, Carlos A. Encarnacion11, Josien Haan12, Amy M. Truitt12, Andrea Menicucci12, William Audeh12, FLEX Investigatorsโ€™ Group13 Background The 80-gene signature Read More

5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial

Publication: St. Gallen Authors: E. Gรถker, M.P. Hendriks, M. van Tilburg, A. Barcaru, L. Mittempergher, A. van Egmond, M. Kleijn and D. Generali Background: The 80-gene signature BluePrintยฎ (BP) discriminates between three distinctive molecular subtypes: Luminal-type, HER2-type and Basal-type.1 Combined with the 70-gene signature MammaPrintยฎ (MP), BP can further stratify Read More

Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients

ย  Publication: Miami Breastย  Authors Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Angela Mislowsky, Carrie Dul, Paul Richards, Mark Gittleman, Stephanie Akbari, Shiyu Wang, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group. Background Increased use of multi-gene expression profiling has enabled refinement Read More

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Lisa Blumencranz, Andrea Menicucci, Shiyu Wang, Amy Truitt, William Audeh, Jolanta L. Baginski, Steven Shivers, Geza Acs, Charles E. Cox, MINT Investigators Group. Background: Elderly breast cancer (BC) patients are an understudied population, with limited evidence regarding treatment options and Read More